Brought to you by 
Third Venture and Tasgen merge to form I-MAB
01 Dec 2017
Executive Summary
Third Venture Biopharma and Tasgen Bio-Tech Co. Ltd. have merged to form a new firm called I-MAB Biopharma, which will focus on development in China of biologics for cancer and autoimmune diseases.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Third Venture and Tasgen merge to form I-MAB
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice